Does the media favor RLAY or ELAN?

In the previous week, Elanco Animal Health had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Elanco Animal Health's score of 0.98 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or RLAY more profitable?

Relay Therapeutics' return on equity of -43.94% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Relay Therapeutics N/A -43.94% -40.11%

Does the media prefer ABVX or RLAY?

In the previous week, Abivax had 7 more articles in the media than Relay Therapeutics. MarketBeat recorded 14 mentions for Abivax and 7 mentions for Relay Therapeutics. Abivax's average media sentiment score of 1.43 beat Relay Therapeutics' score of 1.21 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RLAY or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Axsome Therapeutics and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Axsome Therapeutics' score of 1.18 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or SMMT more profitable?

Relay Therapeutics' return on equity of -43.94% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -43.94% -40.11% Summit Therapeutics N/A -168.94% -141.92%

Does the media prefer RLAY or SMMT?

In the previous week, Summit Therapeutics had 15 more articles in the media than Relay Therapeutics. MarketBeat recorded 22 mentions for Summit Therapeutics and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Summit Therapeutics' score of 0.10 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts rate RLAY or RDY?

Relay Therapeutics currently has a consensus price target of $24.92, suggesting a potential upside of 36.23%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 2.86 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor RLAY or RDY?

In the previous week, Dr. Reddy's Laboratories had 9 more articles in the media than Relay Therapeutics. MarketBeat recorded 16 mentions for Dr. Reddy's Laboratories and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Dr. Reddy's Laboratories' score of -0.19 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Relay Therapeutics (RLAY) Competitors

$18.29 -0.35 (-1.88%)

Closing price 07/28/2026 04:00 PM Eastern

Extended Trading

$18.30 +0.01 (+0.06%)

As of 04:51 AM Eastern

Compare

RLAY vs. ELAN, ABVX, AXSM, SMMT, and RDY

Should you buy Relay Therapeutics stock or one of its competitors? MarketBeat compares Relay Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relay Therapeutics include Elanco Animal Health (ELAN), Abivax (ABVX), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Relay Therapeutics compare to Elanco Animal Health?

Relay Therapeutics (NASDAQ:RLAY) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Relay Therapeutics currently has a consensus target price of $24.92, suggesting a potential upside of 36.23%. Elanco Animal Health has a consensus target price of $28.73, suggesting a potential upside of 12.54%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 1 more articles in the media than Relay Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Elanco Animal Health's score of 0.98 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Elanco Animal Health	-4.95%	7.42%	3.66%

Relay Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Elanco Animal Health has higher revenue and earnings than Relay Therapeutics. Elanco Animal Health is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	228.29	-$276.48M	-$1.57	N/A
Elanco Animal Health	$4.72B	2.70	-$232M	-$0.50	N/A

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Abivax has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

In the previous week, Abivax had 7 more articles in the media than Relay Therapeutics. MarketBeat recorded 14 mentions for Abivax and 7 mentions for Relay Therapeutics. Abivax's average media sentiment score of 1.43 beat Relay Therapeutics' score of 1.21 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics' return on equity of -43.94% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Relay Therapeutics	N/A	-43.94%	-40.11%

47.9% of Abivax shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Relay Therapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Relay Therapeutics	$15.35M	228.29	-$276.48M	-$1.57	N/A

Abivax currently has a consensus price target of $156.50, indicating a potential upside of 25.98%. Relay Therapeutics has a consensus price target of $24.92, indicating a potential upside of 36.23%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Relay Therapeutics beats Abivax on 12 of the 15 factors compared between the two stocks.

How does Relay Therapeutics compare to Axsome Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Axsome Therapeutics has higher revenue and earnings than Relay Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	228.29	-$276.48M	-$1.57	N/A
Axsome Therapeutics	$638.50M	18.88	-$183.17M	-$3.73	N/A

Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Relay Therapeutics currently has a consensus price target of $24.92, suggesting a potential upside of 36.23%. Axsome Therapeutics has a consensus price target of $261.48, suggesting a potential upside of 11.65%. Given Relay Therapeutics' higher probable upside, equities research analysts plainly believe Relay Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Axsome Therapeutics had 8 more articles in the media than Relay Therapeutics. MarketBeat recorded 15 mentions for Axsome Therapeutics and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Axsome Therapeutics' score of 1.18 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Relay Therapeutics' return on equity of -43.94% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Relay Therapeutics beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Summit Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Relay Therapeutics currently has a consensus target price of $24.92, indicating a potential upside of 36.23%. Summit Therapeutics has a consensus target price of $26.15, indicating a potential upside of 108.40%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Relay Therapeutics has higher revenue and earnings than Summit Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	228.29	-$276.48M	-$1.57	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Relay Therapeutics' return on equity of -43.94% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Summit Therapeutics	N/A	-168.94%	-141.92%

Relay Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, indicating that its share price is 226% less volatile than the broader market.

In the previous week, Summit Therapeutics had 15 more articles in the media than Relay Therapeutics. MarketBeat recorded 22 mentions for Summit Therapeutics and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Summit Therapeutics' score of 0.10 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Relay Therapeutics beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Relay Therapeutics compare to Dr. Reddy's Laboratories?

Relay Therapeutics (NASDAQ:RLAY) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Dr. Reddy's Laboratories has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	228.29	-$276.48M	-$1.57	N/A
Dr. Reddy's Laboratories	$3.58B	2.74	$456M	$0.44	26.67

Relay Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Relay Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Dr. Reddy's Laboratories had 9 more articles in the media than Relay Therapeutics. MarketBeat recorded 16 mentions for Dr. Reddy's Laboratories and 7 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.21 beat Dr. Reddy's Laboratories' score of -0.19 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Relay Therapeutics currently has a consensus price target of $24.92, suggesting a potential upside of 36.23%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Relay Therapeutics beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.57B	$3.05B	$7.08B	$12.19B
Dividend Yield	N/A	2.06%	2.66%	8.55%
P/E Ratio	-11.65	20.47	27.28	23.75
Price / Sales	228.29	799.56	578.34	109.45
Price / Cash	N/A	27.27	49.60	59.05
Price / Book	5.59	4.09	10.13	6.06
Net Income	-$276.48M	$67.27M	$3.60B	$336.44M
7 Day Performance	-5.09%	-3.34%	-0.95%	-1.50%
1 Month Performance	-7.35%	-7.64%	-3.60%	-4.62%
1 Year Performance	405.25%	12.49%	20.53%	15.02%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	3.3407 of 5 stars	$18.29 -1.9%	$24.92 +36.2%	+394.3%	$3.57B	$15.35M	N/A	330	News Coverage Positive News
ELAN Elanco Animal Health	3.1331 of 5 stars	$25.18 -2.5%	$28.55 +13.4%	+75.0%	$12.90B	$4.72B	N/A	9,400	Upcoming Earnings
ABVX Abivax	4.0272 of 5 stars	$131.50 -3.8%	$148.54 +13.0%	+86.6%	$11.91B	N/A	N/A	61	Positive News
AXSM Axsome Therapeutics	3.0175 of 5 stars	$221.64 -3.6%	$261.48 +18.0%	+133.3%	$11.84B	$638.50M	N/A	380	Positive News
SMMT Summit Therapeutics	3.5118 of 5 stars	$13.50 -2.2%	$26.97 +99.8%	-54.3%	$10.72B	N/A	N/A	110	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. ELAN, ABVX, AXSM, SMMT, and RDY

How does Relay Therapeutics compare to Elanco Animal Health?

Summary

How does Relay Therapeutics compare to Abivax?

Summary

How does Relay Therapeutics compare to Axsome Therapeutics?

Summary

How does Relay Therapeutics compare to Summit Therapeutics?

Summary

How does Relay Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. ELAN, ABVX, AXSM, SMMT, and RDY

How does Relay Therapeutics compare to Elanco Animal Health?

Do analysts recommend RLAY or ELAN?

Does the media favor RLAY or ELAN?

Is RLAY or ELAN more profitable?

Which has more volatility and risk, RLAY or ELAN?

Which has higher valuation and earnings, RLAY or ELAN?

Do institutionals & insiders have more ownership in RLAY or ELAN?

Summary

How does Relay Therapeutics compare to Abivax?

Which has more volatility and risk, ABVX or RLAY?

Does the media prefer ABVX or RLAY?

Is ABVX or RLAY more profitable?

Do insiders and institutionals believe in ABVX or RLAY?

Which has preferable earnings & valuation, ABVX or RLAY?

Do analysts rate ABVX or RLAY?

Summary

How does Relay Therapeutics compare to Axsome Therapeutics?

Which has better earnings & valuation, RLAY or AXSM?

Which has more volatility & risk, RLAY or AXSM?

Do insiders & institutionals have more ownership in RLAY or AXSM?

Do analysts rate RLAY or AXSM?

Does the media prefer RLAY or AXSM?

Is RLAY or AXSM more profitable?

Summary

How does Relay Therapeutics compare to Summit Therapeutics?

Do insiders & institutionals hold more shares of RLAY or SMMT?

Do analysts prefer RLAY or SMMT?

Which has preferable valuation and earnings, RLAY or SMMT?

Is RLAY or SMMT more profitable?

Which has more volatility and risk, RLAY or SMMT?

Does the media prefer RLAY or SMMT?

Summary

How does Relay Therapeutics compare to Dr. Reddy's Laboratories?

Which has better earnings and valuation, RLAY or RDY?

Which has more volatility & risk, RLAY or RDY?

Is RLAY or RDY more profitable?

Do institutionals & insiders have more ownership in RLAY or RDY?

Does the media favor RLAY or RDY?

Do analysts rate RLAY or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools